ClinicalTrials.gg
CompletedNCT03638180Updated Nov 9, 2018

BLU-5937: First-in-Human, Single and Multiple Doses Escalation, Safety, Tolerability, Pharmacokinetics and Food Effect

A Phase 1 interventional study of BLU-5937 and Placebo in Cough, sponsored by Bellus Health Inc. - a GSK company. Completed at 1 site in Canada. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-11-09.

Sponsored by Bellus Health Inc. - a GSK company (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing BLU-5937 in Cough — 1 open to participants now, 2 under way, 2 of them phase 3. BLU-5937 · Cough.

Enrollment
3rd of 10
90 · median 44
Started
2018
the only one that year
Phase 1
7 of 10
none open now
Registered
1st of 10
by date
Lead sponsor
8 of 10
Bellus Health Inc. - a GSK company

Among the 10 studies testing BLU-5937 in Cough, this one is the 3rd largest by enrollment, is the only one that started in 2018, is one of 7 in phase 1, and was the 1st registered.

Cough

428 studies on the registry are indexed under Cough; 68 are open to participants now.

Browse Cough studies →

Open to participants now

1 of the 10 studies testing BLU-5937 in Cough is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About BLU-5937

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 46 Cough studies recruiting now, 20 (43%) set no upper age limit and 14 (30%) stop at 75 or younger; 10 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing BLU-5937 in Cough, or all of them as a file.
02

Study summary

This is a first-in-human study that will investigate the safety, tolerability and pharmacokinetics of ascending single and multiple doses of BLU-5937 using a double blind, placebo controlled, randomized, adaptive, single center study design. The influence of food on the pharmacokinetics of BLU-5037 will also be investigated.

Read the detailed description

BLU-5937 is a selective P2X3 receptor antagonist being developed for the treatment of chronic cough. This Phase 1 study will investigate the safety, tolerability and pharmacokinetics of ascending single and multiple doses of BLU-5937 administered orally to healthy volunteers.

03

Conditions studied

  • Cough

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult male and/or female (non- or, for women of childbearing potential, using 2 forms of acceptable or agreed to abide by true abstinence),
  • Age: 18 to 55 years (inclusive).
  • (BMI) : ≥18.5 and ≤30 kg/m².
  • Non or ex smoker.

Exclusion criteria

Exclusion Criteria:

  • Any findings from the medical examination (including medical history, physical examination, vital signs, laboratory tests and ) outside from normal and deemed by the investigator to be .
  • Use of any prescription drugs (with the exception of hormone replacement therapy) in the 28 days prior to the first study drug administration, that in the opinion of the investigator would put into question the status of the volunteer as healthy.
  • Volunteers who took an Product in the 28 days prior to the first study drug administration.
  • Volunteers who donated 50 mL or more of blood in the 28 days prior to the first study drug administration.
  • Donation of 500 mL or more of blood in the 56 days prior to the first study drug administration.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    Single Ascending Doses

    Single ascending doses, 6 dose levels

    Drug: BLU-5937 · Drug: Placebo

  • Experimental
    Multiple Ascending Doses

    Multiple ascending doses, 3 dose levels

    Drug: BLU-5937 · Drug: Placebo

Interventions

  • BLU-5937 oral tablet

  • DrugPlacebo

    Matching placebo to BLU-5937

06

What researchers measure

Primary outcomes

  1. Number and severity of treatment emergent adverse events (TEAEs)

    Number and severity of TEAEs collected from dosing until follow up 48 hours after last dose

    Time frame: up to 48 hours after the last dose

Secondary outcomes

  1. Maximum plasma concentration (Cmax)

    To assess Cmax of single and multiple ascending oral doses of BLU-5937

    Time frame: up to 48 hours after the last dose

  2. Area under the curve (AUC)

    To assess AUC of single and multiple ascending oral doses of BLU-5937

    Time frame: up to 48 hours after the last dose

  3. Maximum plasma concentration (Cmax) under fed conditions

    To assess Cmax of a single oral dose of BLU-5937 under fed conditions

    Time frame: up to 48 hours after the last dose

  4. Area under the curve (AUC) under fed conditions

    To assess AUC of a single oral dose of BLU-5937 under fed conditions

    Time frame: up to 48 hours after the last dose

07

Study locations

1 site
  • Alta Sciences Algorithme Pharma
    Mount-Royal, Quebec H3P 3P1, Canada
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Oct 2018, 3 months.

Of 21 phase 1 interventional studies under Cough, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2018
First posted
Aug 20, 2018
StartActual
Jul 9, 2018
Primary completionActual
Oct 25, 2018
CompletionActual
Oct 25, 2018
Last update
Nov 9, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 9, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03638180
Responsible party
Sponsor
First posted
Aug 20, 2018
Start date
Jul 9, 2018
Primary completion
Oct 25, 2018
Completion
Oct 25, 2018
Last update
Nov 9, 2018

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BLU-5937

Start the discussion